Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy

被引：25

作者：

Janjua, Naveed Z. ^{[1
,2
]}

Darvishian, Maryam ^{[1
,2
]}

Wong, Stanley ^{[1
]}

Yu, Amanda ^{[1
]}

Rossi, Carmine ^{[1
,2
]}

Ramji, Alnoor ^{[3
]}

Yoshida, Eric M. ^{[3
]}

Butt, Zahid A. ^{[1
,2
]}

Samji, Hasina ^{[1
,4
]}

Chong, Mei ^{[1
]}

Chapinal, Nuria ^{[1
]}

Cook, Darrel ^{[1
]}

Alvarez, Maria ^{[1
]}

Tyndall, Mark ^{[1
,2
]}

Krajden, Mel ^{[1
,5
]}

Rizi, Seyed Ali Mussavi ^{[6
]}

Gilbert, Mark ^{[1
,2
]}

Wong, Jason ^{[1
,2
]}

机构：

[1] British Columbia Ctr Dis Control, Vancouver, BC, Canada

[2] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada

[3] Univ British Columbia, Div Gastroenterol, Dept Med, Vancouver, BC, Canada

[4] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada

[5] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada

[6] Prov Hlth Serv Author, Performance Measurement & Reporting, Vancouver, BC, Canada

来源：

HEPATOLOGY COMMUNICATIONS | 2019年 / 3卷 / 04期

基金：

加拿大健康研究院;

关键词：

C VIRUS-INFECTION; HEPATITIS-C; GENOTYPE; GLOBAL PREVALENCE; ANTIVIRAL AGENTS; TREATMENT-NAIVE; HCV; SOFOSBUVIR; CARE; INDIVIDUALS;

D O I：

10.1002/hep4.1307

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

We evaluated the effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treating hepatitis C virus (HCV) genotype 1 and SOF/velpatasvir (SOF/VEL) for all genotypes among people who inject drugs (PWID) and those not injecting drugs and who were on or off opioid agonist therapy (OAT). Study participants comprised a population-based cohort in British Columbia, Canada. The British Columbia Hepatitis Testers Cohort includes data on individuals tested for HCV from 1990 to 2016 that are integrated with medical visits, hospitalization, and prescription drug data. We classified study participants as off OAT/recent injection drug use (off-ONIYRIDU), off OAT/past IDU (off-OAT/PIDU), off OAT/no IDU (off-OAT/NIDU), on OAT/IDU (on-OAT/IDU), and on OAT/no IDU (on-OAT/NIDU). We assessed sustained virologic response (SVR) 10 weeks after HCV treatment among study groups treated with LDV/SOF or SOF/VEL until January 13, 2018. Analysis included 5,283 eligible participants: 390 off-OAT/RIDU, 598 off-OAT/ PIDU, 3,515 off-OAT/NIDU, 609 on-OAT/IDU, and 171 on-OAT/NIDU. The majority were male patients (64%74%) and aged >= 50 years (58%-85%). The SVRs for off-OAT/RIDU, off-OAT/PIDU, off-OAT/NIDU, on-OAT/ IDU, and on-OAT/NIDU were 91% (355/390), 95% (570/598), 96% (3,360/3,515), 93% (567/609), and 95% (163/171), respectively. Among those with no SVR, 14 individuals died while on treatment or before SVR assessment, including 4 from illicit drug overdose. In the overall multivariable model, off-OAT/RIDU, on-OAT/IDU, male sex, cirrhosis, treatment duration < 8 weeks, treatment duration 8 weeks, and treatment with SOF/VEL were associated with not achieving SVR. Conclusion: In this large real-world cohort, PWID and/or those on OAT achieved high SVRs, although slightly lower than people not injecting drugs. This finding also highlights the need for additional measures to prevent loss to follow-up and overdose-related deaths among PWID.

引用

页码：478 / 492

页数：15

共 34 条

[1] Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 US Veterans [J].

Backus, L. I. ;

Belperio, P. S. ;

Shahoumian, T. A. ;

Loomis, T. P. ;

Mole, L. A. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (05) :559-573

[2] Real-World Effectiveness of Ledipasvir/Sofosbuvir in 4,365 Treatment-Naive, Genotype 1 Hepatitis C-Infected Patients [J].

Backus, Lisa I. ;

Belperio, Pamela S. ;

Shahoumian, Troy A. ;

Loomis, Timothy P. ;

Mole, Larry A. .

HEPATOLOGY, 2016, 64 (02) :405-414

[3] Belgian experience with direct acting antivirals in people who inject drugs [J].

Bielen, Rob ;

Moreno, Christophe ;

Van Vlierberghe, Hans ;

Bourgeois, Stefan ;

Mulkay, Jean-Pierre ;

Vanwolleghem, Thomas ;

Verlinden, Wim ;

Brixko, Christian ;

Decaestecker, Jochen ;

De Galocsy, Chantal ;

Janssens, Filip ;

Cool, Mike ;

Van Overbeke, Lode ;

Van Steenkiste, Christophe ;

D'heygere, Francois ;

Cools, Wilfried ;

Nevens, Frederik ;

Robaeys, Geert .

DRUG AND ALCOHOL DEPENDENCE, 2017, 177 :214-220

[4] Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study [J].

Blach, Sarah ;

Zeuzem, Stefan ;

Manns, Michael ;

Altraif, Ibrahim ;

Duberg, Ann-Sofi ;

Muljono, David H. ;

Waked, Imam ;

Alavian, Seyed M. ;

Lee, Mei-Hsuan ;

Negro, Francesco ;

Abaalkhail, Faisal ;

Abdou, Ahmed ;

Abdulla, Maheeba ;

Abou Rached, Antoine ;

Aho, Inka ;

Akarca, Ulus ;

Al Ghazzawi, Imad ;

Al Kaabi, Saad ;

Al Lawati, Faryal ;

Al Namaani, Khalid ;

Al Serkal, Youssif ;

Al-Busafi, Said A. ;

Al-Dabal, Layla ;

Aleman, Soo ;

Alghamdi, Abdullah S. ;

Aljumah, Abdulrahman A. ;

Al-Romaihi, Hamad E. ;

Andersson, Monique I. ;

Arendt, Vic ;

Arkkila, Perttu ;

Assiri, Abdullah M. ;

Baatarkhuu, Oidov ;

Bane, Abate ;

Ben-Ari, Ziv ;

Bergin, Colm ;

Bessone, Fernando ;

Bihl, Florian ;

Bizri, Abdul R. ;

Blachier, Martin ;

Blasco, Antonio J. ;

Mello, Carlos E. Brandao ;

Bruggmann, Philip ;

Brunton, Cheryl R. ;

Calinas, Filipe ;

Chan, Henry L. Y. ;

Chaudhry, Asad ;

Cheinquer, Hugo ;

Chen, Chien-Jen ;

Chien, Rong-Nan ;

Choi, Moon Seok .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (03) :161-176

[5]

British Columbia Centre on Substance Use, 2017, GUID CLIN MAN OP US

[6] A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia [J].

Butt, Zahid Ahmad ;

Shrestha, Nabin ;

Wong, Stanley ;

Kuo, Margot ;

Gesink, Dionne ;

Gilbert, Mark ;

Wong, Jason ;

Yu, Amanda ;

Alvarez, Maria ;

Samji, Hasina ;

Buxton, Jane A. ;

Johnston, James C. ;

Cook, Victoria J. ;

Rothe, David ;

Consolacion, Theodora ;

Murti, Michelle ;

Hottes, Travis S. ;

Ogilvie, Gina ;

Balshaw, Robert ;

Tyndall, Mark W. ;

Krajden, Mel ;

Janjua, Naveed Z. .

PLOS ONE, 2017, 12 (08)

[7] Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice? [J].

Christensen, Stefan ;

Buggisch, Peter ;

Mauss, Stefan ;

Boker, Klaus H. W. ;

Schott, Eckart ;

Klinker, Hartwig ;

Zimmermann, Tim ;

Weber, Bernd ;

Reimer, Jens ;

Serfert, Yvonne ;

Wedemeyer, Heiner .

ADDICTION, 2018, 113 (05) :868-882

[8] Effectiveness of 8-or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients [J].

Curry, M. P. ;

Tapper, E. B. ;

Bacon, B. ;

Dieterich, D. ;

Flamm, S. L. ;

Guest, L. ;

Kowdley, K. V. ;

Lee, Y. ;

Milligan, S. ;

Tsai, N. ;

Younossi, Z. ;

Afdhal, N. H. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (05) :540-548

[9] Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review [J].

Degenhardt, Louisa ;

Peacock, Amy ;

Colledge, Samantha ;

Leung, Janni ;

Grebely, Jason ;

Vickerman, Peter ;

Stone, Jack ;

Cunningham, Evan B. ;

Trickey, Adam ;

Dumchev, Kostyantyn ;

Lynskey, Michael ;

Griffiths, Paul ;

Mattick, Richard P. ;

Hickman, Matthew ;

Larney, Sarah .

LANCET GLOBAL HEALTH, 2017, 5 (12) :E1192-E1207

[10] Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Randomized Trial [J].

Dore, Gregory J. ;

Altice, Frederick ;

Litwin, Alain H. ;

Dalgard, Olav ;

Gane, Edward J. ;

Shibolet, Oren ;

Luetkemeyer, Anne ;

Nahass, Ronald ;

Peng, Cheng-Yuan ;

Conway, Brian ;

Grebely, Jason ;

Howe, Anita Y. M. ;

Gendrano, Isaias N. ;

Chen, Erluo ;

Huang, Hsueh-Cheng ;

Dutko, Frank J. ;

Nickle, David C. ;

Bach-Yen Nguyen ;

Wahl, Janice ;

Barr, Eliav ;

Robertson, Michael N. ;

Platt, Heather L. .

ANNALS OF INTERNAL MEDICINE, 2016, 165 (09) :625-+

← 1 2 3 4 →